Back Back
RCB1520 : JHOC-5  update : 2018/08/01
CommentClear cell adenocarcinoma. Said CA125, CA72-4 producing. Application consideration
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Contact Us
RIKEN, BioResource Research Center
Cell Engineering Division
Dr.Cell Bank
Fax. +81-29-836-9130
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC( regarding any kind of for-profit use.
Basic information Depositor Ishikawa, Hiroshi
Originator Ishikawa, H. & Yasuda, M.
Year of deposit 1999
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 54 years
Tissue ovary
Case history Clear cell carcinoma of ovary
Metastastatic ability Yes
Metastatsd tissue lymph node
Classification cancer
Year of origin 1998
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM/HamF12 + 10% FBS + 0.1mM NEAA
Antibiotics Free
Passage method (0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR (human) OK
Isozyme LD, NP
Chromosome mode 56-67(50) : /61(7),62(10),63(20),67(7)/
deposit info
lot info
Reference information Reference 1
User's Publication 12

To topTop
2405  Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5, JHOC-6) of human ovary.  Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H  Hum Cell  1999  12:131-8  PubMed ID: 10695020

To topTop
User's Publication
2934  Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.  Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo  Clin Cancer Res  2004  10:2687-93  PubMed ID: 15102672
7404  Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.  Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.  Mol. Carcinog.  2016  55:832-41  PubMed ID: 25856562
7410  Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.  Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.  Int. J. Oncol.  2015  46:2389-98  PubMed ID: 25846456
8331  Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.  Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.  Int. J. Cancer  2010  128:94-104  PubMed ID: 20309881
10087  Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.  Sato M, Kawana K, Adachi K, Fujimoto A, Taguchi A, Fujikawa T, Yoshida M, Nakamura H, Nishida H, Inoue T, Ogishima J, Eguchi S, Yamashita A, Tomio K, Arimoto T, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.  Oncol. Rep.  2017  37:1883-1888  PubMed ID: 28112360
10161  Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.  Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Ogishima J, Eguchi S, Yamashita A, Tomio K, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.  Int. J. Oncol.  2017  50:1431-1438  PubMed ID: 28259988
11075  ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.  Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.  Oncogene  2018  37(33):4611-4625  PubMed ID: 29760405
11109  Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.  Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, Couderc B, Guillermet-Guibert J, Martinez A.  Oncotarget  2018  9(43):27220-27232  PubMed ID: 29930760
11322  PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.  Kato N, Sato Y, Kamataki A, Fukase M, Uchigasaki S, Kurose A.  Hum. Pathol.  2019    PubMed ID: 30496799
3796  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956
6298  Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.  Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.  Int J Oncol  2008  32(6):1227-35  PubMed ID: 18497984
11632  Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.  Caumanns JJ, van Wijngaarden A, Kol A, Meersma GJ, Jalving M, Bernards R, van der Zee AGJ, Wisman GBA, de Jong S.  Cancer Lett.  2019    PubMed ID: 31319139

Back Back Return Top Page